Norsk
KEY FIGURES
131
NEW IDEAS
14
BILLION NOK COMBINED VALUE
OF PORTFOLIO COMPANIES
15
NEW LICENSE AGREEMENTS
82
NEW PATENT APPLICATIONS
177
NEW CLINICAL STUDIES
417
ONGOING CLINICAL STUDIES
8
NEW COMPANIES ESTABLISHED
43
MILLION NOK TO
NEW RESEARCH
1,1
BILLION NOK IN
PRIVATE CAPITAL RAISED
A word from the CEO
2021 was the year when a great deal of what Inven2 has long been working towards finally bore fruit. It takes a long time to commercialise basic research, and it is therefore important to have faith that the processes involved and the expertise invested in them will produce results.
Read more
Innovation
– how do you take your research to market?
Inven2’s main area of focus is taking research results and turning them into a product or service in a market. This is done through a value chain that starts with idea hunting and marketing of Inven2’s services aimed at researchers at the University of Oslo and Oslo University Hospital.
Read more
CLINICAL TRIALS ARE THE KEY TO MEDICAL DEVELOPMENT
Clinical trials involve testing new drugs and medical equipment on human subjects. Clinical trials can be conducted on both healthy volunteers and patients.
Read moreThe board of directors
Inven2 is one of Norway’s largest technology transfer offices (TTO), and our mandate is to commercialise research on behalf of our owners: the University of Oslo, Oslo University Hospital and the South-Eastern Norway Regional Health Authority.
Our board has broad insight into different fields of research, commercialisation, innovation, start-ups and knowledge-intensive business services.
Employee representative is Siv Merethe Uddeholt, Clinical Contract Manager in Inven2.
Tom Pike chairs the board.
About inven2
Making a difference by transforming knowledge into products and services for the benefit of society.
Research and knowledge are the keys to addressing global challenges relating to health, climate and the environment. Highly capable researchers and clinicians from larger parts Norway report their ideas and discoveries to us. We develop and manage these ideas, and proceed with the ones that can be transformed into products that benefit society.
We have started businesses that develop better cancer therapies, combat antibiotic resistance and identify security breaches in complex IT systems. Two-thirds of our businesses and licences are in the field of life science, since the scientific community we represent is particularly strong in that field.
Another important area for us is to administer agreements on clinical trials on behalf of the hospitals in our region and in the northern part of Norway. We make active endeavours to get more international companies to carry out their clinical trials in Norway. That way, more innovative treatment can benefit more patients in Norway.
Inven2 is a limited company owned by the University of Oslo and Oslo University Hospital. Inven2 currently has 30 employees.
Portfolio businesses
Inven2 has a portfolio comprising 55 companies. 8 new companies were established in 2021. Together, the companies are worth around NOK 15 billion.
The companies raised a total of NOK 1,1 billion for development purposes in 2021. At the same time, NOK 43 million was returned to inventors and to research at the institutions.
Portfolio
Adjutec Pharma AS
Beep Systems AS
cFIRE AS
Crowdo AS
Disputas AS
FoodCapture
Hageleie AS
Mine Opplysninger AS
Prevention AS
SporTech AS
Stilyagi AS
Products
Inven2 want to make a difference by transforming research and knowledge into products and services for the benefit of society. We have contributed to the launching of many products and services. Here is a selection.
Ecosystem
Inven2 is part of a vital, ever-growing ecosystem in research and development. The area near Inven2’s premises in Oslo Science Park is home to a number of clusters and incubators, as well as the University of Oslo and Oslo University Hospital.
Read more